LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
30.64
-0.17 (-0.55%)
At close: Oct 29, 2025, 4:00 PM EDT
30.64
0.00 (0.00%)
After-hours: Oct 29, 2025, 4:10 PM EDT
LENZ Therapeutics Revenue
LENZ Therapeutics had revenue of $5.00M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $5.00M.
Revenue (ttm)
$5.00M
Revenue Growth
n/a
P/S Ratio
170.08
Revenue / Employee
$454,545
Employees
11
Market Cap
820.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 15.00M | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLENZ News
- 9 hours ago - LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025 - GlobeNewsWire
- 4 weeks ago - LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States - PRNewsWire
- 4 weeks ago - LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States - GlobeNewsWire
- 7 weeks ago - LENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - LENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 2 months ago - LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences - GlobeNewsWire
- 3 months ago - LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia - GlobeNewsWire
- 3 months ago - LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire